Most children with hepatoblastoma manifest, at the time of LT, a decrease in renal function due to chemotherapy that could be further deteriorated by the use of calcineurin inhibitors. The purpose of this work was to examine the long‐term follow‐up of renal function in a cohort of children transplanted for unresectable hepatoblastoma. We present a retrospective observational study of 10 pediatric patients who received a LT for unresectable hepatoblastoma between 1996 and 2016. All patients included in this study were followed up on a regular basis and were assessed for GFR before transplantation and at least once a year during follow‐up. All patients received standardized chemotherapy treatment for hepatoblastoma and immunosuppression according to hospital protocols. There was a marked decrease in GFR at the time of the LT in five patients presenting renal complications during the pretransplant cycles of chemotherapy. Three patients, one of them with prior kidney involvement, presented complications after LT, namely acute kidney failure and decrease in GFR. Those patients who presented with the lowest GFR at the time of LT eventually recovered renal function at levels similar to the rest of the group on follow‐up. Chemotherapy‐induced nephrotoxicity is a concern in patients treated for hepatoblastoma. Some individuals will develop low GFR after chemotherapy; therefore, strict follow‐up is recommended, as low GFR may affect the doses of subsequent chemotherapy and immunosuppression. Stabilization of GFR levels and occasional improvement can be observed in the post‐transplant period.

中文翻译：

---

肝移植不可切除的肝母细胞瘤的肾小球滤过率。

大多数肝母细胞瘤患儿在 LT 时表现出由于化疗导致的肾功能下降，而使用钙调磷酸酶抑制剂可能会进一步恶化。这项工作的目的是检查一组因不可切除的肝母细胞瘤而移植的儿童的肾功能的长期随访。我们对 10 名在 1996 年至 2016 年间因不可切除的肝母细胞瘤接受 LT 的儿科患者进行了回顾性观察研究。 本研究中的所有患者均定期随访，并在移植前评估 GFR，在随访期间至少每年评估一次-向上。所有患者均根据医院方案接受肝母细胞瘤的标准化化疗和免疫抑制治疗。在移植前化疗周期中出现肾脏并发症的 5 名患者在 LT 时 GFR 显着降低。三名患者，其中一名先前有肾脏受累，在 LT 后出现并发症，即急性肾功能衰竭和 GFR 降低。那些在 LT 时呈现最低 GFR 的患者最终在随访时恢复了与该组其他人相似的肾功能水平。化疗引起的肾毒性是接受肝母细胞瘤治疗的患者的一个问题。有些人在化疗后会出现低 GFR；因此，建议严格随访，因为低 GFR 可能会影响后续化疗和免疫抑制的剂量。在移植后阶段可以观察到 GFR 水平的稳定和偶尔的改善。